Physician profile
Grace Bialy
NPI 1427002351
$2,135.27
in general payments reported to CMS, 2019-2025
22 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $27.98 · 2022: $257 · 2023: $568 · 2024: $697 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574 · Education: $66.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.46 |
| Education | $66.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $270.74 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $255.86 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $242.76 | 2019-2025 | Farxiga |
| Calliditas Therapeutics US INC. | $203.16 | 2023-2025 | Tarpeyo |
| Amgen INC. | $183.28 | 2024-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $165.02 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $114.51 | 2023-2024 | Lupkynis |
| Vifor Pharma, INC. | $105.13 | 2019-2023 | Veltassa |
| Novo Nordisk INC | $77.26 | 2024-2025 | Rivfloza, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $74.37 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $63.08 | 2024-2025 | |
| Daiichi Sankyo INC. | $56.12 | 2019 | |
| Azurity Pharmaceuticals, INC. | $53.48 | 2023-2024 | Edarbi, Edarbi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.91 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $48.65 | 2023-2024 | Benlysta, Jesduvroq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $32.44 | 2024 | Jardiance |
| Ardelyx, INC. | $32.36 | 2024 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $30.47 | 2025 | Terlivaz |
| Arbor Pharmaceuticals, INC. | $27.23 | 2019 | |
| Nxstage Medical, INC. | $19.96 | 2022 | |
| Horizon Therapeutics Plc | $16.17 | 2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $14.31 | 2024 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Bialy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.